Supernus to Host Fourth Quarter and Full Year 2015 Earnings Conference Call
February 18 2016 - 4:30PM
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty
pharmaceutical company focused on developing and commercializing
products for the treatment of central nervous system (CNS)
diseases, today announced that the Company expects to report the
financial results for the fourth quarter and full year of 2015
after 5:00 PM ET on Wednesday, March 2, 2016.
Jack Khattar, President and Chief Executive Officer, and Greg
Patrick, Chief Financial Officer, will host a conference call to
present the fourth quarter and full year 2015 results on Thursday,
March 3, 2016 at 9:00 AM ET. Following the presentation, the call
will be open for questions.
A live webcast will be available at www.supernus.com.
Please refer to the information below for conference call
dial-in information. Callers should dial in approximately 10
minutes prior to the start of the call.
|
Conference
dial-in: |
(877) 288-1043 |
|
|
International
dial-in: |
(970) 315-0267 |
|
|
Conference
ID: |
47017444 |
|
|
Conference Call Name:
|
Supernus
Pharmaceuticals 4Q 2015 Earnings Conference Call |
Following the live call, a replay will be available on the
Company's website under the 'Investors' section. The webcast will
be available on the Company's website for 60 days following the
live call.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system diseases. The Company has two
marketed products for epilepsy, Oxtellar XR® (extended-release
oxcarbazepine) and Trokendi XR® (extended-release topiramate). The
Company is also developing several product candidates to address
large market opportunities in psychiatry, including SPN-810 for the
treatment of impulsive aggression in patients who are already being
treated with standard ADHD medication. SPN-812 is being developed
for treatment of ADHD.
CONTACTS:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
Westwicke Partners
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Apr 2023 to Apr 2024